Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
GLP-1/GIP dual agonist tirzepatide in SYNERGY-NASH trial The SYNERGY-NASH phase 2 trial evaluated tirzepatide, a dual GIP/GLP-1 receptor agonist, in patients with MASH and F2/F3 fibrosis
Kumar calls Retatrutide the next generation of GLP-1s, explaining that the investigational medication stands apart because it targets three hormone pathways: GLP-1, GIP and glucagon
S.PadmanabanA.Rodriguez-ZasS.et al
LillyDirect sells Zepbound in single-dose vials: $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for 7.5 to 15 mg doses, but only if you refill within 45 days of your previous delivery
The Science of Formulation We often get asked why we choose liquid liposomal formats over traditional capsules
US$ 21.98
US$ 28.51
US$ 23.86
US$ 27.09
US$ 25.13
